ATE165977T1 - Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie - Google Patents

Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Info

Publication number
ATE165977T1
ATE165977T1 AT93902861T AT93902861T ATE165977T1 AT E165977 T1 ATE165977 T1 AT E165977T1 AT 93902861 T AT93902861 T AT 93902861T AT 93902861 T AT93902861 T AT 93902861T AT E165977 T1 ATE165977 T1 AT E165977T1
Authority
AT
Austria
Prior art keywords
analgesia
enhancement
methods
opiate
producing
Prior art date
Application number
AT93902861T
Other languages
English (en)
Inventor
Alan Justice
Tejinder Singh
Kishor Chandra Gohil
Karen L Valentino
George P Miljanich
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of ATE165977T1 publication Critical patent/ATE165977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93902861T 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie ATE165977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81475991A 1991-12-30 1991-12-30

Publications (1)

Publication Number Publication Date
ATE165977T1 true ATE165977T1 (de) 1998-05-15

Family

ID=25215938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902861T ATE165977T1 (de) 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Country Status (8)

Country Link
US (3) US5587454A (de)
EP (1) EP0625162B1 (de)
AT (1) ATE165977T1 (de)
AU (1) AU689438B2 (de)
CA (1) CA2151741C (de)
DE (1) DE69225499T2 (de)
SG (1) SG50624A1 (de)
WO (1) WO1993013128A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
DE69627153T2 (de) * 1995-06-27 2003-12-04 Elan Pharmaceuticals, Inc.(N.D.Ges.D.Staates Delaware) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1997004797A1 (en) * 1995-07-26 1997-02-13 Warner-Lambert Company Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US6060271A (en) * 1996-02-09 2000-05-09 Cornell Research Foundation, Inc. CDNA fragments corresponding to voltage gated sodium channel genes expressed in peripheral nerve
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6489119B1 (en) * 1996-03-29 2002-12-03 Elan Pharmaceuticals, Inc. Analgesic screening method and composition
JP4332902B2 (ja) 1997-04-25 2009-09-16 味の素株式会社 新規ジヒドロピリジン誘導体
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
ATE279919T1 (de) * 1997-08-15 2004-11-15 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
CA2224066A1 (en) * 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
US6350762B1 (en) 1997-12-22 2002-02-26 Ajinomoto Co., Inc. Dihydropyridine derivative
WO1999054350A1 (en) * 1998-04-16 1999-10-28 The University Of Queensland Novel omega conotoxin peptides
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor
JP2003525582A (ja) 1999-01-22 2003-09-02 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション アルファ−コノトキシンペプチド
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
EP1191022A4 (de) 1999-06-23 2002-09-18 Ajinomoto Kk Neuartige dihydropyridin-derivate
AU5568200A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Dihydropyridine derivative
EP1210100B1 (de) 1999-08-10 2006-06-14 UAB Research Foundation Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten
JP2003533178A (ja) * 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
US20030119731A1 (en) * 2000-07-21 2003-06-26 University Of Utah Research Foundation Omega-conopeptides
EP1311283A4 (de) * 2000-07-21 2004-09-01 Univ Utah Res Found Omega-conopeptide
JP2005500258A (ja) * 2001-03-23 2005-01-06 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
WO2003086408A1 (en) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
ES2383358T3 (es) * 2002-12-02 2012-06-20 Xenome Ltd Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal
US7507717B2 (en) * 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7365050B2 (en) * 2003-08-08 2008-04-29 The Regents Of The University Of California Methods for modulating a drug-related effect or behavior
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) * 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
WO2007041360A2 (en) * 2005-09-30 2007-04-12 The Board Of Trustees Of The University Of Illinois Peptides and calcium regulation in mammalian cells
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
IN266803B (de) 2005-12-22 2015-06-03 Newron Pharm Spa
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
TR201802576T4 (tr) 2007-06-15 2018-03-21 Newron Pharm Spa Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN117405760A (zh) * 2023-09-15 2024-01-16 延边大学 一种测定蛋白质与小分子的结合常数的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5231011A (en) * 1991-04-18 1993-07-27 University Of Utah Segregated folding determinants for small disulfide-rich peptides

Also Published As

Publication number Publication date
EP0625162B1 (de) 1998-05-13
US5364842A (en) 1994-11-15
AU689438B2 (en) 1998-04-02
DE69225499T2 (de) 1999-02-04
CA2151741A1 (en) 1993-07-08
US5859186A (en) 1999-01-12
EP0625162A1 (de) 1994-11-23
US5587454A (en) 1996-12-24
HK1013832A1 (en) 1999-09-10
AU3428093A (en) 1993-07-28
CA2151741C (en) 2001-12-11
WO1993013128A1 (en) 1993-07-08
SG50624A1 (en) 1998-07-20
DE69225499D1 (de) 1998-06-18

Similar Documents

Publication Publication Date Title
DE69225499D1 (de) Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
ATE181320T1 (de) Verfahren zur herstellung von mischungen von n- acylierten aminosaeuren
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
DE69434703D1 (de) Verfahren zur Erzeugung von DSA-Unterschriften mit preisgünstigen tragbaren Einheiten
DE68928934D1 (de) Verfahren zur herstellung von menschlicher dnase
DE59000200D1 (de) Verfahren zur gewinnung von erdgas.
ATE326476T1 (de) Verfahren zur herstellung von phosphorothioat- oligomeren
DE59611165D1 (de) Verfahren zur Herstellung von Ausweiskarten
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE69813212D1 (de) Verfahren zur erzeugung von proteinhydrolysaten
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE241012T1 (de) Verfahren zur herstellung von humanen relaxin
EP1023451A4 (de) Methoden zur replikation von viren in von monozyten abgeleiteten makrophagenkulturen
DE3865869D1 (de) Kohlenstoffhaltiges sorbentmittel zur trennung von pyrogenen und dessen verwendung zur erzeugung von reinem wasser.
DE3583896D1 (de) Verfahren und vorrichtung zur herstellung von weissen zementklinkern.
ATE120206T1 (de) Peptide, die die bindung des von-willebrand- faktors inhibieren.
ATE184917T1 (de) Rekombinante methode und wirt zur herstellung von xylitol
ATE164065T1 (de) Neues verfahren zur behandlung von depression
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
ATE71109T1 (de) Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung.
ATE204291T1 (de) Verfahren zur herstellung von peptiden und n- carbamoyl-geschützten peptiden
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE3853156D1 (de) Polyestergewebe zur herstellung von elektrophoresegelen und elektrophoresegel.
DE3881685D1 (de) Kombiniertes verfahren zur erzeugung von chlordioxid und natriumhydroxid.
ATE80594T1 (de) Verfahren zur herstellung von boriden der seltenen erden.